Therapeutic antibody development company Patrys (ASX:PAB) has announced new pre-clinical data for its lead asset, PAT-DX1, from a study conducted by Professor Terrence Johns of the Telethon Kids Cancer Centre.
Partrys' candidate in combination improves survival in brain cancer model
August 11, 2022 Australian Biotech
Latest Video
New Stories
-
New Zealand moves again to make it easier to access medicines
July 11, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 10 July
July 10, 2025 - - Podcast -
'The debate is frustrating but it is an opportunity to amplify acknowledged concerns'
July 10, 2025 - - Latest News -
Medibank to subsidise pharmacogenetic testing for members
July 10, 2025 - - Latest News -
Is this the missing link in pharma engagement strategies?
July 9, 2025 - - Latest News -
Stakeholders welcome medicinal cannabis crackdown
July 9, 2025 - - Latest News -
Might Australia be just a little hypocritical on pharmaceutical tariffs?
July 9, 2025 - - Latest News